Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)-Reference-Cited by-同舟云学术

Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)

Published:2023-08-21 Issue:10 Volume:40 Page:4639-4656
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Araie Makoto,Sugiyama Kazuhisa,Aso Kenji,Kanemoto Koji,Iwata Ryo,Hollander David A.,Senchyna Michelle,Kopczynski Casey C.

Funder

Aerie Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02550-w.pdf

Reference38 articles.

1. Araie M, Sugiyama K, Aso K, et al. Phase 2 randomized clinical study of netarsudil ophthalmic solution in Japanese patients with primary open-angle glaucoma or ocular hypertension. Adv Ther. 2021;38(4):1757–75.

2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–90.

3. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–40.

4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.

5. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13 (Discussion 829–30).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-03-02

2. Update on Diagnosis and Treatment of Uveitic Glaucoma;Journal of Clinical Medicine;2024-02-20

3. Advantages and disadvantages of using Rho kinase inhibitors to reduce intraocular pressure;Expert Review of Ophthalmology;2024-02-12

4. ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs;Journal of Clinical Medicine;2023-10-25